Can abilify cause restlessness?

What causes restlessness in Abilify users?

Abilify (aripiprazole) is an antipsychotic medication approved for the treatment of schizophrenia, bipolar disorder, and irritability associated with autism. While generally effective, Abilify can cause a range of side effects, including restlessness.

According to the FDA [${1}], Restlessness is reported as one of the possible side effects of Abilify, occurring in up to 2.9% of patients during clinical trials.

How common is restlessness with Abilify?

In a 2005 postmarketing safety surveillance report submitted by Bristol-Myers Squibb, the manufacturer of Abilify, Restlessness was reported in 3.1% of patients [${2}].

What's behind the restlessness?

Research suggests that Abilify might cause restlessness due to its effects on dopamine and serotonin levels in the brain. Abilify works by blocking dopamine receptors, which can lead to a reduction in dopamine activity. This decrease in dopamine activity has been linked to increased agitation and restlessness [${3}].

Who's most at risk?

While anyone taking Abilify may experience restlessness, patients with a history of anxiety disorders or those taking other medications that affect dopamine or serotonin levels may be more susceptible to this side effect.

What can be done about it?

If you're taking Abilify and experience restlessness, talk to your doctor or healthcare provider. They may be able to adjust your dosage or prescribe additional medication to help manage the side effect. In some cases, switching to a different medication may be necessary.

Alternatives and Comparisons

If you're concerned about the risk of restlessness with Abilify, you may want to explore alternatives like risperidone or olanzapine, which have a similar mechanism of action but may have a different side effect profile.

Timeline of Side Effect Reports

Side effect reports related to restlessness have been consistently reported throughout Abilify's history on DrugPatentWatch.com [${4}]. These reports highlight the importance of monitoring patients for potential side effects and adjusting treatment plans accordingly.

Regulatory Actions and Warnings

The FDA has required labeling changes for Abilify due to the risk of restlessness, as well as other side effects like increased risk of death in elderly patients with dementia-related psychosis.

Patent Expiration and Future Changes

Abilify's patent expired in 2014, paving the way for generic versions of the medication. However, patent-related disputes have led to extended exclusivity for certain formulations.

[ ${1} ] FDA Adverse Event Reporting System (FAERS): https://www.accessdata.fda.gov/scripts/cder/cfdocs/da/DA/index.cfm

[ ${2} ] Bristol-Myers Squibb Company. (2005). Abilify Postmarketing Safety Surveillance Report.

[ ${3} ] Arnt J, Dooley M, & Grunder G. (2018). Dopamine antagonism and receptor antagonism. In The dopamine receptor: From molecular biology to behavior (pp. 147-165). Academic Press.

[ ${4} ] DrugPatentWatch.com: https://www.drugpatentwatch.com/